A study published by the American Orthopedic Foot and Ankle Society indicates patients receiving Cartiva implants for the treatment of hallux rigidus face a 79% implant failure risk within two years of receiving Cartiva. Researchers found 64% of patients who received a Cartiva implant for hallux rigidus experienced device failure within four weeks of the surgery. The study found the risk of failure increased as time passed, reporting a 79% failure rate in patients by 19 months post-surgery.